Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Pick a track — progress rings update as you complete lessons.
12 lessons
10mThe most useful peptide research is not the loudest. It is the stuff that changes the question from 'does it work?' to 'who does it help, for what outcome, and with what tradeoffs?'
8mRegulation does not settle the peptide debate by itself. It forces clearer questions about sourcing, safety, evidence, and who is responsible when claims move faster than data.
9mSports medicine keeps pulling peptides into the conversation because recovery pressure is real. The hard part is separating promising biology from weak evidence, gray-market hype, and antidoping risk.
7mPeptide therapy searches on TikTok jumped 459% in early 2026. Here's what's driving the explosion, which peptides are trending, and what you need to know before you start.
9mFor years, GLP-1 therapy meant a weekly injection. The FDA just changed that. Foundayo is the first oral GLP-1 approved for weight management, and the implications for the peptide community go far beyond convenience.
10mMost fat-loss compounds either suppress appetite or boost energy expenditure. 5-Amino-1MQ does something different — it blocks the enzyme that burns through your NAD+ and keeps fat cells from ever getting broken down. Here's why it stacks so well with Reta and MOTS-C.
10mMOTS-C activates AMPK and drives mitochondrial adaptation — but does daily use over months cause your body to stop responding? Here's what the research and user experience actually says about long-term MOTS-C protocols.
9mThe FDA's April 15, 2026 reclassification of 12 research peptides marks the most significant regulatory shift in the space since the 2023 compounding crackdown. Here's a breakdown of the affected compounds, the new compliance landscape, and how to think about your protocol going forward.
8mMOTS-C is mitochondria-encoded and activates AMPK through a pathway that's less prone to classic receptor downregulation. Here's how to structure long-term use for sustained results.
10mAn FDA advisory panel scheduled for July 2026 could reshape access to 12 peptides — including BPC-157, MOTS-C, and GHK-Cu. Here's what's on the table, what reclassification would mean in practice, and how to prepare for either outcome.
10mMost people know GHK-Cu for skin and wound healing. What they don't know: it's one of the most potent epigenetic regulators ever studied, influencing over 4,000 human genes — many tied directly to aging, inflammation, and tissue repair.
14mThe peptide space is shifting from weight loss toward longevity. Explore the science behind peptides designed to slow aging, repair cellular damage, and extend healthspan.
Also available at /blog for legacy links.